РОЛЬ ЖИДКОСТНОЙ БИОПСИИ В ВЫБОРЕ ТАКТИКИ ЛЕЧЕНИЯ НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЁГКОГО
PDF

Ключевые слова

НЕМЕЛКОКЛЕТОЧНЫЙ РАК ЛЁГКОГО
ЖИДКОСТНАЯ БИОПСИЯ
МУТАЦИОННЫЙ ПРОФИЛЬ
МИНИМАЛЬНАЯ РЕЗИДУАЛЬНАЯ БОЛЕЗНЬ
ОБЗОР

Аннотация

В данной статье описываются потенциальные возможности применения жидкостной биопсии при немелкоклеточном раке лёгкого в качестве метода определения мутационного профиля, а также минимальной резидуальной болезни после радикального хирургического лечения. Описаны преимущества и недостатки данного метода по сравнению с традиционной тканевой биопсией. Представлены потенциальные возможности применения жидкостной биопсии для персонализации лечения.

https://doi.org/10.37469/0507-3758-2020-66-5-457-464
PDF

Библиографические ссылки

Miranda B. Carper and Pier Paolo Claudio. Clinical potential of gene mutations in lung cancer. Clin Transl Med. 2015; 4: 33. doi: 10.1186/s40169-015-0074-1.

Minji Lim, Vijaya sunkara, Chi-Ju Kim et al. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA). Article in Micro machines. 2018; 9(3):100. doi: 10.3390/mi9030100.

Camila D.M. Campos, Joshua M. Jackson, Matgorzata A. Witek et al. Molecular Profiling of Liquid Biopsy Samples for Precision Medicine. Cancer J. 2018; 24(2): 93-103. doi: 10.1097/PP0.0000000000000311.

Sato Y, Matoba R., Kato K. Recent Advances in Liquid Biopsy in Precision Oncology Research. Biol Pharm Bull. 2019;42(3):337-342. doi: 10.1248/bpb.b18-00804.

Jatta Saarenheimo, Natalja Eigeliene, Heidi Andersen et al. The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer. Front. Oncol. 2019; https://doi.org/10.3389/fonc.2019.00129.

Pasini L., Ulivi P. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. J. Clin. Med. 2019; 8(7): 998. https:// doi.org/10.3390/jcm8070998.

Liu Q., Qiao L., Liang N., Xie J. et al. The relationship between vasculogenic mimicry and epithelial-mesenchymal transitions. J Cell Mol Med. 2016; 20(9): 1761-1769. doi: 10.1111/jcmm.12851.

Kloten V., Lampignano R., Krahn T. et al. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC. Cells. 2019; 8(8): 809. doi: 10.3390/cells8080809.

Shigematsu H., Lin L., Takahashi T. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J. Natl Cancer-Inst. 2005; 97(5), 339-346. doi:10.1093/jnci/dji055.

Qin B.D., Jiao X.D., Yuan L.Y et al. The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. Onco Targets Ther. 2018; 11:4739-45. doi: 10.2147/OTT.S167346.

Eric Santoni-Rugiu, Linea C. Melchior, Edyta M. Urbanska et al. Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers. 2019; 11(7): 923. https://doi.org/10.3390/can-cers11070923.

Liu Y, Sun L., Xiong Z.-C. et al. Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs. Onco Targets Ther. 2017; 10: 2267-2279. doi: 10.2147/OTT.S133082.

Fang W., Huang Y, Hong S. et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer. 2019; 19(1):595. doi: 10.1186/ s12885-019-5820-0.

Mayo-de-Las-Casas C., Jordana-Ariza N., Garzn-Ibaez M. et al. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions. Ann Oncol. 2017; 28:2248-55. doi: 10.1093/annonc/mdx288.

Tran H., Lam V., Vasquez M. et al. P1.01-98 Outcomes in Advanced NSCLC Patients Treated with 1st Line EGFR-TKI Based on Mutation Detection from Tissue or cfDNA-Based Genomic Sequencing. https://doi.org/10.1016/j. jtho.2019.08.813.

Han B., Tjulandin S., Hagiwara K. et al. GFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. Lung Cancer. 2017; 113: 37-44. https://doi.org/10.1016/jtung-can.2017.08.021.

Reck M., Hagiwara K., Han B. et al. ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. J Thorac Oncol. 2016; 11(10):1682-9. doi: 10.1016/j. jtho.2016.05.036.

Goldman J.W., Noor Z.S., J Remon et all. Are liquid biopsies a surrogate for tissue EGFR testing? Annals of Oncology. 2018; 29(1): i38-i46. https://doi.org/10.1093/ annonc/mdx706.

Kuo C.-Y, Lee M.-H., Tsai M.-J. et al. The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with EGFR Mutations. J Clin Med. 2019; 8(11). pii: E1758. doi: 10.3390/jcm8111758.

Adrian G. Sacher, Cloud Paweletz, Suzanne E. Dahlberg et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016; 2(8):1014-22. doi: 10.1001/jamaoncol.2016.0173.

Li, C., Jia, R., Liu, H. et al. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors. Diagn Pathol. 2018; 13, 49. doi: 10.1186/s13000-018-0728-6.

Ana Finzel , Helen Sadik , Gregori Ghitti et al. The combined analysis of solid and liquid biopsies provides additional clinical information to improve patient care. J Cancer Metastasis Treat. 2018;4:21. doi: 10.20517/23944722.2018.10.

Chenguang Li, Rui Jia, Hailin Liu et al. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors. Diagn Pathol. 2018; 13, 49 doi:10.1186/ s13000-018-0728-6.

Lee J.Y, Qing X., Xiumin W. et all. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget. 2016;7(6):6984-93. doi: 10.18632/oncotarget.6874.

Tseng J.-S., Yang T.-Y, Tsai C.-R. et al. Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology. 2015; 10(4), 603610. doi:10.1097/jto.0000000000000443.

Sorensen B.S., Wu L., Wei W. et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014;120(24):3896-901. doi: 10.1002/cncr.28964.

Provencio M., Torrente M., Calvo V. et all. Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. Oncotarget. 2017;9(1):488-494. doi: 10.18632/oncotarget.22470.

Gray J.E., Peled N., Markovets A. et al. Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA. Annals of Oncology. 2019; 30 (sup-pl_5): v851-v934. doi: 10.1093/annonc/mdz394.

Park C.-K., Cho H.-J., Choi Y-D. et al. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort Cancer Res Treat. 2019; 51(2): 777-787. doi: 10.4143/ crt.2018.387.

Chudacek J., Bohanes T., Klein J. et al. Detection of minimal residual disease in lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(2):189-93. doi: 10.5507/bp.2013.019.

Hosch S.B., Scheunemann P., Izbicki J.R. Minimal residual disease in non-small-cell lung cancer. Semin Surg Oncol. 2001;20(4):278-81. doi: 10.1002/ssu.1045.

Лактионов К.К., Артамонова Е.В., Бредер В.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли: Практические рекомендации RUSSCO#3s2. 2019; 9: 32-48. doi: 10.18027/2224-5057-2019-9-3s2-32-48.

Ye T., Chen H. Adjuvant targeted therapy for resected NSCLC: to be or not to be? J Thorac Dis. 2018; 10(Suppl 26): S3297-S3299. doi: 10.21037/jtd.2018.07.111.

Karen Kelly, Nasser K. Altorki, Wilfried E.E. et all. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 2015;33(34), 4007-4014. doi:10.1200/jco.2015.61.8918.

Herbreteau G., Vall e A., Charpentier S. et al. Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. Vol. 11, Supplement 1 (January 2019): Journal of Thoracic Disease (Advances in Theranostic Biomarkers for Lung Cancer: from Clinical to Molecular Pathology) Submitted Oct 02, 2018. Accepted for publication Nov 30, 2018.doi: 10.21037/jtd.2018.12.18.

Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995; 311:899-909.

Nagasaka M., Gadgeel S.M. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 2018;18(1):63-70. doi: 10.1080/14737140.2018.1409624.

Chaudhuri A.A., Chabon J.J., Lovejoy A.F. et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov 2017;7:1394-403. doi:10.1158/2159-8290.CD-17-0716.

Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.

Copyright (c) 2020 Константин Лактионов, Ксения Саранцева, Елена Реутова, А. Казаков, А. Арзуманян, Н. Москалюк